WO2022049531A1 - Process for the preparation of colostrum concentrate - Google Patents
Process for the preparation of colostrum concentrate Download PDFInfo
- Publication number
- WO2022049531A1 WO2022049531A1 PCT/IB2021/058056 IB2021058056W WO2022049531A1 WO 2022049531 A1 WO2022049531 A1 WO 2022049531A1 IB 2021058056 W IB2021058056 W IB 2021058056W WO 2022049531 A1 WO2022049531 A1 WO 2022049531A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- colostrum
- process according
- fact
- concentrate
- mbar
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
- A23C9/206—Colostrum; Human milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Definitions
- the present invention relates to a process for the preparation of colostrums concentrate.
- serum, placenta and colostrum contain numerous biologically active factors, e.g. vital protein factors such as cytokines, growth factors, chemotactic factors, complement factors and other active components.
- vital protein factors such as cytokines, growth factors, chemotactic factors, complement factors and other active components.
- biologically active factors or “active biological factors” relates to components that have a certain biological activity, including all substances that have a therapeutic or beneficial effect on the body.
- Colostrum is particularly rich in these factors, which are in particular INFy, TNFa, TGF01, IGF-1, immunoglobulins such as IgG, IgM and IgA, IL-2 and complement factors C3A and C4A.
- the main aim of the present invention is to provide a process for the preparation of colostrum concentrate which makes it possible to keep the biologically active components of native colostrum unaltered.
- One object of the present invention is to provide a process for the preparation of colostrum concentrate which has low operating times, compared to known processes, allowing the biological effectiveness of the components contained therein to be maintained.
- Another object of the present invention is to devise a process for the preparation of colostrum concentrate which enables the aforementioned drawbacks of the prior art to be overcome within the framework of a simple, rational, easy and effective to use as well as affordable solution.
- the objects mentioned above are achieved by the colostrum concentrate having the characteristics of claim 12.
- the present invention relates to a process for the preparation of colostrum concentrate.
- the process comprises the following phases of: a) supply of colostrum; b) concentration of colostrum comprising the steps of: bi) subjecting colostrum to controlled vacuum conditions; bi) applying a temperature lower than 45°C to colostrum.
- colostrum is supplied whole in the hours following delivery.
- colostrum is collected in the hours immediately after delivery, i.e., within 36 hours of delivery.
- colostrum is collected within 24 hours of delivery.
- colostrum is of bovine, equine or caprine origin.
- the supply phase involves freezing the colostrum.
- the colostrum supplied frozen undergoes melting at a temperature of between 4°C and 15°C.
- the supply phase involves supplying colostrum in a freeze-dried or dehydrated state.
- colostrum is solubilized in water.
- solubilization ratio between colostrum and water is between 30:70 and 60:40.
- controlled vacuum conditions comprise pressure values lower than the atmospheric pressure.
- such pressure values are lower than 300 mbar.
- such pressure values are lower than 150 mbar.
- the pressure values are comprised between 40 mbar and 80 mbar.
- the process comprises the step of applying temperature values comprised between 20°C and 40°C.
- the process comprises the step of applying temperature values comprised between 25°C and 35°C.
- such temperature values are lower than 30°C.
- the concentration phase comprises an evaporation step of the water contained in the colostrum.
- the evaporation step allows removing the water from the colostrum allowing it to be concentrated at a concentration ratio of 5:1 with respect to the native colostrum. This means that 1 kg of colostrum concentrate is obtained for 5 kg of native colostrum by carrying out the process according to the present invention.
- the concentration phase is carried out until a density value of colostrum comprised between 1,100 mg/kg and 1,250 mg/kg is reached.
- the process comprises an extraction phase of the latter.
- the aforementioned extraction phase is carried out through separation by gravity.
- This separation by gravity is achieved by means of centrifugation at 10,000 RPM for an operating time of substantially 120 seconds.
- the aforementioned extraction phase is carried out by reverse osmosis.
- reverse osmosis also known as hyperfiltration, is the process whereby solvent molecules, in the present case residual water, are forced from the more concentrated solution, in the present case colostrum concentrate, to the less concentrated solution obtained by applying a pressure greater than the osmotic pressure to the colostrum concentrate.
- the process comprises a microbiological stabilization phase of the colostrum concentrate carried out through one of: UV rays, microfiltration, ozone flow and high pressure treatment.
- the present invention relates to colostrum concentrate obtainable from the process described above and having a furosine content of less than 0.1 mg/lOOg of colostrum concentrate.
- the aforementioned colostrum has a density lower than 5 kg/1, preferably lower than 2 kg/1.
- Example 1 Qualitative-quantitative analysis of colostrum concentrate obtained by the process according to the invention.
- Table 1 shows a furosine content of less than 0.1 mg/lOOg colostrum.
- the process described in the present invention offers the advantage of obtaining colostrum concentrate characterized by the presence of active biological factors comprising immunoglobulins specific to the animal species from which it is derived and which may be used for therapeutic purposes.
- the process according to the present invention offers the advantage of obtaining the aforementioned active biological factors in a biologically active form, thanks to the non-use of any treatment which could cause denaturation of the proteins and modification of their tertiary structure, such as high temperatures or low pH values.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising colostrum obtained from the previously described process together with other pharmacologically acceptable excipients and/or adjuvants.
- composition is suitable for topical application or oral administration.
- composition is suitable for use in the treatment of diseases requiring tissue repair or regeneration, the latter being selected from the list comprising: ulcers, skin lesions and mucosal lesions.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
Abstract
The process for the preparation of colostrum concentrate, comprising the following steps of: a) supply of colostrum; b) concentration of the colostrum comprising the steps of: b1) subjecting the colostrum to controlled vacuum conditions; b2) applying a temperature lower than 45°C to the colostrum.
Description
PROCESS FOR THE PREPARATION OF COLOSTRUM
CONCENTRATE
Technical Field
The present invention relates to a process for the preparation of colostrums concentrate.
Background Art
The fact is known that serum, placenta and colostrum contain numerous biologically active factors, e.g. vital protein factors such as cytokines, growth factors, chemotactic factors, complement factors and other active components.
It should be noted that in the context of the present disclosure the term “biologically active factors” or “active biological factors” relates to components that have a certain biological activity, including all substances that have a therapeutic or beneficial effect on the body.
Colostrum is particularly rich in these factors, which are in particular INFy, TNFa, TGF01, IGF-1, immunoglobulins such as IgG, IgM and IgA, IL-2 and complement factors C3A and C4A.
The concentration of these factors is at its highest within twenty-four hours of delivery and then decreases dramatically in the following hours.
It is, therefore, of paramount importance that colostrum be processed in the immediate postnatal hours using rapid concentration procedures.
In order to speed up the operational steps necessary to carry out concentration procedures, the latter have process conditions that are often detrimental to the biologically active components of colostrum.
In order to ensure that these components do not lose their effectiveness, it is in fact essential that they retain their relative native structure.
Currently, in order to reduce operating times, these concentration procedures require the colostrum to be subjected to high temperatures or low pH values, which cause, e.g., the denaturation of many of the proteins it contains.
Alternatively, other known concentration procedures involve the use of membranes through which the colostrum is made to pass under high pressure values causing the denaturation of many biologically active components
contained therein.
In view of these characteristics, the need is particularly felt to develop processes for concentrating colostrum containing active biological factors unaltered with respect to native colostrum.
Description of the Invention
The main aim of the present invention is to provide a process for the preparation of colostrum concentrate which makes it possible to keep the biologically active components of native colostrum unaltered.
One object of the present invention is to provide a process for the preparation of colostrum concentrate which has low operating times, compared to known processes, allowing the biological effectiveness of the components contained therein to be maintained.
Another object of the present invention is to devise a process for the preparation of colostrum concentrate which enables the aforementioned drawbacks of the prior art to be overcome within the framework of a simple, rational, easy and effective to use as well as affordable solution.
The aforementioned objects are achieved by the present process for the preparation of colostrum concentrate having the characteristics of claim 1.
In a further aspect, the objects mentioned above are achieved by the colostrum concentrate having the characteristics of claim 12.
Furthermore, the objects mentioned above are achieved by the pharmaceutical composition having the characteristics of claim 14.
Embodiments of the Invention
In a first aspect the present invention relates to a process for the preparation of colostrum concentrate.
The process comprises the following phases of: a) supply of colostrum; b) concentration of colostrum comprising the steps of: bi) subjecting colostrum to controlled vacuum conditions; bi) applying a temperature lower than 45°C to colostrum.
According to a preferred embodiment of the process according to the invention,
colostrum is supplied whole in the hours following delivery.
This means that colostrum is collected in the hours immediately after delivery, i.e., within 36 hours of delivery.
Preferably, colostrum is collected within 24 hours of delivery.
This means that colostrum does not undergo any treatment aimed at modifying its native properties.
Advantageously, colostrum is of bovine, equine or caprine origin.
Alternatively, the supply phase involves freezing the colostrum.
In this case, the colostrum supplied frozen undergoes melting at a temperature of between 4°C and 15°C.
In a further embodiment of the process according to the invention, the supply phase involves supplying colostrum in a freeze-dried or dehydrated state. In the latter case, colostrum is solubilized in water.
In detail, the solubilization ratio between colostrum and water is between 30:70 and 60:40.
In order to promote water removal, controlled vacuum conditions comprise pressure values lower than the atmospheric pressure.
Preferably, such pressure values are lower than 300 mbar.
Advantageously, such pressure values are lower than 150 mbar.
According to a preferred embodiment of the process according to the present invention, the pressure values are comprised between 40 mbar and 80 mbar.
In association with the step of subjecting colostrum to controlled vacuum conditions, the process comprises the step of applying temperature values comprised between 20°C and 40°C.
According to a preferred embodiment, the process comprises the step of applying temperature values comprised between 25°C and 35°C.
Alternatively, such temperature values are lower than 30°C.
Next, the concentration phase comprises an evaporation step of the water contained in the colostrum.
In detail, the evaporation step allows removing the water from the colostrum allowing it to be concentrated at a concentration ratio of 5:1 with respect to the
native colostrum. This means that 1 kg of colostrum concentrate is obtained for 5 kg of native colostrum by carrying out the process according to the present invention.
It should be underlined that the synergistic combination of controlled vacuum conditions, i.e. the application of pressure values lower than 300 mbar and temperature values lower than 45 °C, makes it possible to achieve the boiling of the colostrum and, therefore, the evaporation of the water contained therein under conditions that are not harmful to the biological active components in the native colostrum.
Advantageously, the concentration phase is carried out until a density value of colostrum comprised between 1,100 mg/kg and 1,250 mg/kg is reached.
If residual water remains in colostrum concentrate, the process comprises an extraction phase of the latter.
Preferably, the aforementioned extraction phase is carried out through separation by gravity.
This separation by gravity is achieved by means of centrifugation at 10,000 RPM for an operating time of substantially 120 seconds.
Alternatively, the aforementioned extraction phase is carried out by reverse osmosis.
As is well known, reverse osmosis, also known as hyperfiltration, is the process whereby solvent molecules, in the present case residual water, are forced from the more concentrated solution, in the present case colostrum concentrate, to the less concentrated solution obtained by applying a pressure greater than the osmotic pressure to the colostrum concentrate.
Next, the process comprises a microbiological stabilization phase of the colostrum concentrate carried out through one of: UV rays, microfiltration, ozone flow and high pressure treatment.
In a further aspect, the present invention relates to colostrum concentrate obtainable from the process described above and having a furosine content of less than 0.1 mg/lOOg of colostrum concentrate.
In addition, the aforementioned colostrum has a density lower than 5 kg/1,
preferably lower than 2 kg/1.
Example 1: Qualitative-quantitative analysis of colostrum concentrate obtained by the process according to the invention.
MATERIAL AND METHODS A qualitative-quantitative analysis of colostrum obtained by the process according to the present invention is shown in table 1.
Table 1
The analysis in Table 1 shows a furosine content of less than 0.1 mg/lOOg colostrum.
Further confirmation of the efficacy of the process according to the present invention shows the total absence of Salmonella spp, Listeria monocytogenes and Campylobacter spp.
In particular, the process described in the present invention offers the advantage of obtaining colostrum concentrate characterized by the presence of active biological factors comprising immunoglobulins specific to the animal species from which it is derived and which may be used for therapeutic purposes.
It should be pointed out that the synergistic combination of IgG, IgA and IgM with albumin, lactoferrin and lysozyme makes it possible to obtain a surprising healing effect in the process of tissue reconstruction following wounds.
In particular, the process according to the present invention offers the advantage of obtaining the aforementioned active biological factors in a biologically active form, thanks to the non-use of any treatment which could cause denaturation of the proteins and modification of their tertiary structure, such as high temperatures or low pH values.
This is of fundamental importance, since in order to perform their functions within the body, the active biological factors must not lose their native structure, since loss of structure corresponds to loss of efficacy.
In this regard, in a further aspect, the present invention relates to a pharmaceutical composition comprising colostrum obtained from the previously described process together with other pharmacologically acceptable excipients and/or adjuvants.
Moreover, the aforementioned composition is suitable for topical application or oral administration.
Furthermore, this composition is suitable for use in the treatment of diseases requiring tissue repair or regeneration, the latter being selected from the list
comprising: ulcers, skin lesions and mucosal lesions.
It has in practice been ascertained that the described invention achieves the intended objects.
In particular, the fact is emphasized that the special measure of allowing the colostrum to boil at temperatures lower than 45°C in combination with the application of controlled vacuum makes it possible to obtain colostrum concentrate having the biologically active components in their native state, i.e. unaltered from the time of collection in the hours immediately following delivery.
Claims
8
1) Process for the preparation of colostrum concentrate, comprising the following steps of: a) supply of colostrum; b) concentration of said colostrum comprising the steps of: bi) subjecting said colostrum to controlled vacuum conditions; bz) applying a temperature lower than 45°C to said colostrum.
2) Process according to claim 1, characterized by the fact that said controlled vacuum conditions comprise pressure values lower than the atmospheric pressure.
3) Process according to one or more of the preceding claims, characterized by the fact that said pressure values are lower than 300 mbar.
4) Process according to one or more of the preceding claims, characterized by the fact that said pressure values are lower than 150 mbar.
5) Process according to one or more of the preceding claims, characterized by the fact that said pressure values are comprised between 40 mbar and 80 mbar.
6) Process according to one or more of the preceding claims, characterized by the fact that said temperature is comprised between 20°C and 40°C.
7) Process according to one or more of the preceding claims, characterized by the fact that said temperature is comprised between 25°C and 35°C.
8) Process according to one or more of the preceding claims, characterized by the fact that said temperature is lower than 30°C.
9) Process according to one or more of the preceding claims, characterized by the fact that said concentration phase comprises an evaporation step of the water contained in said colostrum.
10) Process according to one or more of the preceding claims, characterized by the fact that it comprises an extraction phase of the residual water contained in said colostrums concentrate.
11) Process according to one or more of the preceding claims, characterized by the fact that said extraction phase is carried out through separation by gravity.
12) Process according to one or more of the preceding claims, characterized by
9 the fact that it comprises a microbiological stabilization phase of said colostrum concentrate carried out through one of: UV rays, microfiltration, ozone flow and high pressure treatment.
13) Process according to one or more of the preceding claims, characterized by the fact that said concentration phase is carried out until a density value of said colostrum comprised between 1,100 mg/kg and 1,250 mg/kg is reached.
14) Colostrum concentrate obtainable through the process according to one or more of the preceding claims having a content of furosin lower than 0.1 mg/lOOg of said colostrum concentrate. 15) Colostrum according to claim 14 having a density lower than 5 kg/1, preferably lower than 2 kg/1.
16) Pharmaceutical composition comprising colostrum concentrate according to claims 14 or 15 together with other pharmacologically acceptable excipients and/or adjuvants. 17) Pharmaceutical composition according to claim 16 suitable for topical application or oral administration.
18) Pharmaceutical composition according to claims 16 or 17 for use in the treatment of diseases requiring tissue repair or regeneration, said diseases being selected from the list comprising: ulcers, skin lesions and mucosal lesions.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21778224.2A EP4208032A1 (en) | 2020-09-03 | 2021-09-03 | Process for the preparation of colostrum concentrate |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102020000020971 | 2020-09-03 | ||
IT102020000020971A IT202000020971A1 (en) | 2020-09-03 | 2020-09-03 | PROCEDURE FOR THE PREPARATION OF CONCENTRATED COLOSTRUM |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022049531A1 true WO2022049531A1 (en) | 2022-03-10 |
Family
ID=73139295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2021/058056 WO2022049531A1 (en) | 2020-09-03 | 2021-09-03 | Process for the preparation of colostrum concentrate |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4208032A1 (en) |
IT (1) | IT202000020971A1 (en) |
WO (1) | WO2022049531A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ239466A (en) * | 1990-08-17 | 1993-12-23 | Us Agriculture | Desalted colostrum: spray dried product from retentate of |
WO1995000155A1 (en) * | 1993-06-23 | 1995-01-05 | Viable Bioproducts Ltd. | Method for the improvement of wound healing and compositions therefor |
CZ279422B6 (en) * | 1992-04-28 | 1995-04-12 | Biofeed S.R.O. | Process for preparing loose , biologically valuable feeding mixtures suitable for storage |
CN1173288A (en) * | 1997-08-28 | 1998-02-18 | 王文荣 | Milk powder containing specific immunity globulin and its prodn. method |
WO1998051316A1 (en) * | 1997-05-09 | 1998-11-19 | Vander Way Limited | Pharmaceutical formulations containing colostrum and the use of colostrum for the treatment of affections of the oral cavity |
-
2020
- 2020-09-03 IT IT102020000020971A patent/IT202000020971A1/en unknown
-
2021
- 2021-09-03 EP EP21778224.2A patent/EP4208032A1/en active Pending
- 2021-09-03 WO PCT/IB2021/058056 patent/WO2022049531A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ239466A (en) * | 1990-08-17 | 1993-12-23 | Us Agriculture | Desalted colostrum: spray dried product from retentate of |
CZ279422B6 (en) * | 1992-04-28 | 1995-04-12 | Biofeed S.R.O. | Process for preparing loose , biologically valuable feeding mixtures suitable for storage |
WO1995000155A1 (en) * | 1993-06-23 | 1995-01-05 | Viable Bioproducts Ltd. | Method for the improvement of wound healing and compositions therefor |
WO1998051316A1 (en) * | 1997-05-09 | 1998-11-19 | Vander Way Limited | Pharmaceutical formulations containing colostrum and the use of colostrum for the treatment of affections of the oral cavity |
CN1173288A (en) * | 1997-08-28 | 1998-02-18 | 王文荣 | Milk powder containing specific immunity globulin and its prodn. method |
Non-Patent Citations (1)
Title |
---|
CHELACK B J ET AL: "Evaluation of methods for dehydration of bovine colostrum for total replacement of normal colostrum in calves", CANADIAN VETERINARY JOURNAL, 1 July 1993 (1993-07-01), Canada, pages 407 - 412, XP055797173, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1686489/pdf/canvetj00368-0025.pdf> [retrieved on 20210420] * |
Also Published As
Publication number | Publication date |
---|---|
EP4208032A1 (en) | 2023-07-12 |
IT202000020971A1 (en) | 2022-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS6011424A (en) | Fibroblast growth factor and characteristics display | |
JP4260877B2 (en) | Virus inactivation method | |
JP4688092B2 (en) | Method for obtaining a protein fraction enriched in active TGF-β, protein fraction and therapeutic application | |
US8993733B2 (en) | Procedure for obtaining a composition containing growth factors from a blood compound, and composition obtained by said procedure | |
Bessho et al. | Purification of bone morphogenetic protein derived from bovine bone matrix | |
RU2366294C1 (en) | Dietary supplement "mobelis" and its production method | |
Baker et al. | Effect of the amino acids and dialyzable constituents of embryonic tissue juice on the growth of fibroblasts | |
EP4208032A1 (en) | Process for the preparation of colostrum concentrate | |
WO2019187200A1 (en) | Growth factor mixture and method for preparing same | |
US4882421A (en) | Pharmaceutical for treating tumors and method for making it | |
EP3411384B1 (en) | Extraction process from colostrum | |
Jadhav et al. | Antivenin production in India | |
CN106167797B (en) | The lyophilized preparation and preparation method thereof of human fibrin dissolution proenzyme | |
NO793412L (en) | PROCEDURE FOR PREPARING TRANSFER FACTOR AGAINST PATHOGEN ANTIGEN | |
EP3177636B1 (en) | Process for the preparation of high purity mixtures of protein factors from bovine colostrum | |
JPH0788397B2 (en) | Tissue-derived tumor growth inhibitor | |
TWI645038B (en) | Preparation method of placental active ingredient capable of improving stem cell survival rate | |
RU2397672C1 (en) | Method of complex girasol processing | |
KR20190142826A (en) | A method of purified snake venom from which toxic components of snake venom | |
CA2814180C (en) | A method of preserving growth factors derived from platelets | |
RU2398472C1 (en) | Method of complex treatment of girasol | |
RU2399629C1 (en) | Method of complex girasol processing | |
RU2318406C1 (en) | Method for production of biologically active supplement (bas) from law molecular milk cation proteins and obtained bas | |
CN105420330B (en) | Preparation method of raja porosa chondroprotein antioxidant peptide | |
CN104606231A (en) | Method for preparing hepatocyte growth-promoting factor stock solution and frozen powder-injection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21778224 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021778224 Country of ref document: EP Effective date: 20230403 |